Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder
- PMID: 34854947
- DOI: 10.1007/s00228-021-03246-2
Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder
Abstract
Purpose: To develop and validate a population pharmacokinetic (PPK) model of valproic acid (VPA) in adult Chinese patients with bipolar disorder, and provide guidance for individualized therapy in this population.
Methods: A total of 1104 serum concentrations from 272 patients were collected in this study. The data analysis was performed using a nonlinear mixed-effects modeling approach. Covariates included demographic parameters, biological characteristics, and concomitant medications. Bootstrap validation (1000 runs), normalized prediction distribution error (NPDE), and external validation of 50 patients were employed to evaluate the final model.
Results: A one-compartment model with first-order absorption and elimination was developed for VPA extended-release tablets. VPA clearance was significantly influenced by three variables: sex (12% higher in male patients), daily dose (increasing with the 0.13 exponent), and body weight (increasing with the 0.56 exponent). Typical values for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) for a female patient weighing 70 kg administered VPA 1000 mg/day were 0.18 h-1, 0.46 L/h, and 12.84 L, respectively. The results of model evaluation indicated a good stable and precise performance of the final model.
Conclusions: A qualified PPK model of VPA was developed in Chinese patients with bipolar disorder. This model could be used as a suitable tool for the personalization of VPA dosing for bipolar patients.
Keywords: Bipolar disorder; Population pharmacokinetics; Valproic acid.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients.Eur J Drug Metab Pharmacokinet. 2021 May;46(3):353-371. doi: 10.1007/s13318-021-00673-5. Epub 2021 Mar 6. Eur J Drug Metab Pharmacokinet. 2021. PMID: 33677821
-
Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.Eur J Clin Pharmacol. 2018 May;74(5):583-591. doi: 10.1007/s00228-018-2414-8. Epub 2018 Jan 16. Eur J Clin Pharmacol. 2018. PMID: 29340733
-
Population Pharmacokinetics of Valproic Acid in Patients with Mania: Implication for Individualized Dosing Regimens.Clin Ther. 2017 Jun;39(6):1171-1181. doi: 10.1016/j.clinthera.2017.04.005. Epub 2017 May 5. Clin Ther. 2017. PMID: 28483293
-
Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder.Expert Rev Clin Pharmacol. 2022 May;15(5):621-635. doi: 10.1080/17512433.2022.2075849. Epub 2022 Jun 2. Expert Rev Clin Pharmacol. 2022. PMID: 35536685
-
A systematic review of population pharmacokinetics of valproic acid.Br J Clin Pharmacol. 2018 May;84(5):816-834. doi: 10.1111/bcp.13510. Epub 2018 Feb 28. Br J Clin Pharmacol. 2018. PMID: 29328514 Free PMC article.
Cited by
-
Prediction Trough Concentrations of Valproic Acid Among Chinese Adult Patients with Epilepsy Using Machine Learning Techniques.Pharm Res. 2025 Jan;42(1):79-91. doi: 10.1007/s11095-025-03817-3. Epub 2025 Jan 22. Pharm Res. 2025. PMID: 39843764
-
Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: Effect of ABCB1 gene polymorphism.Front Pharmacol. 2022 Nov 25;13:1037239. doi: 10.3389/fphar.2022.1037239. eCollection 2022. Front Pharmacol. 2022. PMID: 36506519 Free PMC article.
-
Retrospective Analysis of Steady-State Sodium Valproate Plasma Concentrations in Chinese Patients With Bipolar Disorder: Impact of Demographic and Clinical Characteristics.Ther Drug Monit. 2024 Oct 1;46(5):658-663. doi: 10.1097/FTD.0000000000001199. Epub 2024 Apr 19. Ther Drug Monit. 2024. PMID: 38648661 Free PMC article.
-
Predictors of valproic acid steady-state serum levels in adult and pediatric psychiatric inpatients: a comparative analysis.Psychopharmacology (Berl). 2024 Sep;241(9):1883-1894. doi: 10.1007/s00213-024-06603-y. Epub 2024 May 11. Psychopharmacology (Berl). 2024. PMID: 38733528
-
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.Clin Pharmacokinet. 2022 Apr;61(4):527-537. doi: 10.1007/s40262-021-01077-z. Epub 2021 Nov 17. Clin Pharmacokinet. 2022. PMID: 34786650 Free PMC article.
References
-
- McIntyre RS, Berk M, Brietzke E, Goldstein BI, Lopez-Jaramillo C, Kessing LV, Malhi GS, Nierenberg AA, Rosenblat JD, Majeed A, Vieta E, Vinberg M, Young AH, Mansur RB (2020) Bipolar disorders. Lancet 396(10265):1841–1856. https://doi.org/10.1016/S0140-6736(20)31544-0 - DOI - PubMed
-
- Rantala MJ, Luoto S, Borraz-Leon JI, Krams I (2021) Bipolar disorder: An evolutionary psychoneuroimmunological approach. Neurosci Biobehav Rev 122:28–37. https://doi.org/10.1016/j.neubiorev.2020.12.031 - DOI - PubMed
-
- Vigo D, Thornicroft G, Atun R (2016) Estimating the true global burden of mental illness. Lancet Psychiatry 3(2):171–178. https://doi.org/10.1016/S2215-0366(15)00505-2 - DOI - PubMed
-
- Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68(3):241–251. https://doi.org/10.1001/archgenpsychiatry.2011.12 - DOI - PubMed - PMC
-
- Bowden CL (2003) Valproate. Bipolar Disord 5(3):189–202. https://doi.org/10.1034/j.1399-5618.2003.00031.x - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical